Rein Therapeutics Receives FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis Phase 2 RENEW trial underway; interim data expected in H2 2026. Credit: Rein Therapeutics Subscribe now Already have an account? Sign in.
